Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification

Journal of Clinical Oncology

Volumn 19, Issue 10, 2001, Pages 2587-2595

  Seidman, Andrew D ^a   Fornier, Monica N ^b   Esteva, Francisco J ^b   Tan, Lee ^b   Kaptain, Stamatina ^b   Bach, Ariadne ^b   Panageas, Katherine S ^b   Arroyo, Crispinita ^b   Valero, Vicente ^b   Currie, Violante ^b   Gilewski, Teresa ^b   Theodoulou, Maria ^b   Moynahan, Mary Ellen ^b   Moasser, Mark ^b   Sklarin, Nancy ^b   Dickler, Maura ^b   D'Andrea, Gabriella ^b   Cristofanilli, Massimo ^b   Rivera, Edgardo ^b   Hortobagyi, Gabriel N ^b   Norton, Larry ^b   Hudis, Clifford A ^b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HEART FUNCTION; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; METASTASIS; NEUROTOXICITY; ONCOGENE NEU; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035873815     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.10.2587     Document Type: Article

References (42)

1. Akiyama T, Sudo C, Ogawara H, et al: The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646, 1986
2. Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGC receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985
3. Chazin VR, Kaleko M, Miller AD, et al: Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor. Oncogene 7:1859-1866, 1992
4. Di Fiore PP, Pierce JH, Kraus MH, et al: ErbB2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182, 1987
5. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 235:177-235, 1987
6. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 7:1049-1056, 1992
7. Andrulis IL, Bull SB, Blackstein ME, et al: neu/erbB-2 amplification identifies a poor-prognosis group ot women with node-negative breast cancer. J Clin Oncol 16:1340-1349, 1998
8. Ravdin PM, Chamness GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - A review. Gene 159:19-27, 1995
9. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
10. Berger MS, Locher GW, Saurer S, et al: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243, 1998
11. Dowsett M, Cooke T, Ellis I, et al: Assessment of HER2 status in breast cancer: Why, when, and how? Eur J Cancer 36:170-176, 2000
12. Jacobs TW, Gown AM, Yaziji H, et al: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17:1974-1982, 1999
13. Jacobs TW, Gown AM, Yaziji H, et al: Specificity of HercepT-est in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17:1983-1987, 1999
14. Roche PC, Ingle JN: Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol 17:434, 1999 (letter)
15. Maia DM: Immunohistochemical assays for HER2 overexpression. J Clin Oncol 17:1650, 1999 (letter)
16. Persons DL, Borelli KA, Hsu PH: Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 10:720-727, 1997
17. HER overexpression in human breast cancer using molecular and immunohistochemical methods. Cancer Invest 18:336-342, 2000
18. Jimenez RE, Wallis T, Tabasczka P, et al: Determination of HER-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 13:37-45, 2000
19. Pauletti G, Godolphin W, Press MF, et al: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescent in situ hybridization. Oncogene 13:63-72, 1996
20. Hynes NE, Gerber HA, Saurer S, et al: Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J Cell Biochem 39:167-173, 1989
21. HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 55:5400-5407, 1995
22. Harwerth IM, Wels W, Schlegel J, et al: Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumor cell growth. Br J Cancer 68:1140-1145, 1993
23. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
24. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
25. Vogel C, Cobleigh M, Tripathy D, et al: First-line, nonhormonal treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody). Proc Am Soc Clin Oncol 19:71a, 2000 (abstr 275)
26. Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998
27. Pietras RJ, Pegram MD, Finn RS, et al: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17:2235-2249, 1998
28. Pegram M, Hsu S, Lewis G, et al: Inhibitory effects of combination of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251, 1999
29. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
30. Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a, 1998 (abstr 377)
31. Norton L, Slamon D, Leyland-Jones B, et al: Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer. Proc Am Soc Clin Oncol 18:127a, 1999 (abstr 483)
32. Hudis C, Seidman A, Paton V, et al: Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials. Breast Cancer Res Treat 50:232, 1998 (abstr)
33. Seidman AD, Hudis CA, Albanel J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361, 1998
34. Perez EA, Irwin DH, Patel R, et al: A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 18:126a, 1999 (abstr 480)
35. Waintraub SE, Cantwell S, DeVries J: Phase II study to evaluate the efficacy of weekly paclitaxel (WP) in patients with metastatic breast cancer (MBC) who have failed prior anthracycline (A) +/-taxane (T) therapy. Proc Am Soc Clin Oncol 19:121a, 2000 (abstr 470)
36. Sola C, Lluch A, Garcia-Conde J, et al: Phase II study of weekly paclitaxel (P) treatment in recurrent breast cancer after high-dose chemotherapy (HDC). Proc Am Soc Clin Oncol 18:65a, 1999 (abstr 245)
37. Mickiewicz E, Alvarez AM, Brosio C, et al: A promising second line treatment with weekly Taxol (T) in anthracycline recurrent, advanced breast cancer (ABC) patients (PTS). Proc Am Soc Clin Oncol 18:135a, 1999 (abstr 515)
38. Alvarez AM, Mickiewicz E, Brosio C, et al: Reinduction of response with weekly Taxol (T) in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 18:165a, 1999 (abstr 636)
39. Breier S, Lebedinsky C, Ayiviri A, et al: Long-term weekly paclitaxel (P) in metastatic breast cancer (MBC): A phase II trial in pretreated patients (pts). Proc Am Soc Clin Oncol 17:192a, 1998 (abstr)
40. Pestalozzi BC, Brignoli S: Trastuzumab in CSF. J Clin Oncol 18:2350-2351, 2000 (letter)
41. Freilich RJ, Seidman AD, DeAngelis LM: Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 76:232-236, 1995
42. Mass RD, Sanders C, Charlene K, et al: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol 19:75a, 2000 (abstr 291)